Oppenheimer Reaffirms “Hold” Rating for Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reiterated by investment analysts at Oppenheimer in a research note issued to investors on Wednesday.

Several other equities research analysts have also recently commented on TEVA. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th. Goldman Sachs Group raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target on the stock in a research report on Monday, October 1st. Morgan Stanley boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 3rd. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $25.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $21.58.

Shares of NYSE TEVA opened at $23.84 on Wednesday. The firm has a market capitalization of $23.48 billion, a P/E ratio of 6.07, a P/E/G ratio of 7.08 and a beta of 0.77. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 1-year low of $11.44 and a 1-year high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.11. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.00 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries will post 2.78 earnings per share for the current year.

In related news, VP Richard Daniell sold 2,488 shares of the company’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the transaction, the vice president now owns 2,488 shares in the company, valued at approximately $58,940.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Deborah A. Griffin sold 2,376 shares of the company’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the transaction, the insider now owns 2,376 shares in the company, valued at approximately $56,334.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,531 shares of company stock worth $152,749. 0.43% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC grew its stake in Teva Pharmaceutical Industries by 315,000.0% in the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock valued at $136,000 after buying an additional 6,300 shares during the last quarter. Wealthstreet Investment Advisors LLC acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $200,000. MAI Capital Management acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $204,000. Greenleaf Trust acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $215,000. Finally, Rehmann Capital Advisory Group grew its stake in Teva Pharmaceutical Industries by 136.2% in the 2nd quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock valued at $219,000 after buying an additional 5,201 shares during the last quarter. Institutional investors and hedge funds own 65.10% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Trading Strategy Examples and Plans

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply